Salute e Benessere

ISOMORPHIC LABS ANNOUNCES STRATEGIC MULTI-TARGET RESEARCH COLLABORATION WITH…

"Isomorphic Labs and Novartis hold a shared purpose to reimagine medicine to improve and extend people's lives," said Demis Hassabis, CEO and founder of Isomorphic Labs. "We are delighted to embark upon this integrated way of working, bringing Isomorphic's state-of-the-art AI and technology platform, including the next-generation AlphaFold model, and access to massive computing power to Novartis, an established leader in the creation of innovative medicines." "Isomorphic…
PR Newswire
07/01/2024

Calliditas Therapeutics appoints Maria Törnsén as President North America

"We are pleased to welcome Ms Törnsén to the executive management team as President of our US operations. She brings invaluable experience from building commercial organisations, driving growth and profitability in the area of rare diseases, which will be critical as we target the next step in our development." said CEO Renée Aguiar-Lucander. "I also want to thank Mr Udell for his valuable contribution to the build-up of the US organisation and its early commercial success."…
PR Newswire
07/01/2024

Calliditas to present at JP Morgan Healthcare Conference

Åsa Hillsten, Head of IR & Sustainability, Calliditas Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email:asa.hillsten@calliditas.com The information was sent for publication, through the agency of the contact person set out above, onJanuary 7, 2024at3:00 p.m. CET. About Calliditas Calliditas Therapeutics is a biopharma company headquartered inStockholm, Sweden, focused on identifying, developing, and commercializing novel...
PR Newswire
07/01/2024

Hansa Biopharma provides update on business and key financials ahead of the JP…

Management will be available for meetings in San Francisco during the J.P. Morgan Conference week, January 8-11, 2024. Susan Noonan is coordinating the schedule on behalf of Hansa Biopharma and can be reached at susan@sanoonan.com. Management will be available for meetings inSan Franciscoduring the J.P. Morgan Conference week,January 8-11, 2024.Susan Noonanis coordinating the schedule on behalf of Hansa Biopharma and can be reached atsusan@sanoonan.com . The latest investor...
PR Newswire
06/01/2024

Shares reverse split

Press release Ecully, January 5, 2024 – 6.00 pm Reverse split of Spineway shares Reverse split by exchange of 2,000 existing shares for 1 new shareStart of share split period:January 25, 2024 Effective date of share split:February 27, 2024Spineway, a specialist in innovative implants for the treatment of severe spine disorders, announces that it has decided to carry out a reverse split of its share capital on the basis of 1 new share for 2,000 old shares...
Nasdaq GlobeNewswire
05/01/2024

Ipsen - Monthly information relative to the total number of voting rights and…

Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1)31 December 202383,814,526Gross total* of...
Nasdaq GlobeNewswire
05/01/2024

LANEIGE EXPANDS PARTNERSHIP WITH ACTRESS SYDNEY SWEENEY AS GLOBAL AMBASSADOR

The impact that Sweeney's partnership had on Laneige US during their partnership? "A great example of the magnitude of our partnership with Sydney would be our social follower growth. Since the first announcement of Sydney as our US ambassador in spring 2022, we experienced an immediate 227% surge in Tiktok followers and 53% growth in Instagram followers. One behind the scenes video of Sydney on a Laneige production set went viral three times over, accumulating 72 million views across…
PR Newswire
05/01/2024

Ibuprofen Market Size 2024 - is Expected to Grow USD 112.3 Million by 2029 at a…

Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-28E9344/Ibuprofen_Market Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-28E9344/Ibuprofen_Market Major Factors Driving the Growth of Ibuprofen Market: Because of the rising prevalence of pain and inflammatory diseases worldwide, as well as the popularity of self-medication and over-the-counter medications, consumers are increasingly turning to Ibuprofen for...
PR Newswire
05/01/2024

Tiziana Life Sciences to Present at Biotech Showcase Conference in San…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at Biotech Showcase, San Francisco, January 8-10, 2024. The presentation will be primarily focused on the recent commencement of the phase 2 trial with intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive...
Nasdaq GlobeNewswire
05/01/2024

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco…

LONDON and NEW YORK, Jan.05, 2024(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, is pleased to announce that it will be presenting at Biotech Showcase in San Francisco, January 8-10 2024. The OKYO management team will also be...
Nasdaq GlobeNewswire
05/01/2024

Novartis expands production of Pluvicto™ with addition of its largest and most…

FDA approval of the company's second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyondNew 70,000-square foot RLT facility is the company's largest and most advanced in the world to date and centrally located in the US to maximize access for patients and treatment centersWith four active RLT manufacturing sites and unconstrained supply, Novartis can sufficiently meet current and future demand as ongoing...
Nasdaq GlobeNewswire
05/01/2024

Kohler Brings Design Leadership and Smart Home Wellness Experiences to CES 2024

Kohler incorporates advanced form and function, intuitive controls, and seamless connectivity to help customers enjoy the wellness benefits of exceptional design solutions and luxury spa experiences at home. Kohlerincorporates advanced form and function, intuitive controls, and seamless connectivity to help customers enjoy the wellness benefits of exceptional design solutions and luxury spa experiences at home. These products will be highlighted, among others, at the Kohler CES booth...
PR Newswire
05/01/2024

Revagenix, Inc. Announces Series B Financing to Develop Novel Antibiotics and…

Tenmile managing director Steve Burnell, PhD said Revagenix represented a beacon of hope in the fight against antibiotic resistance. "Our decision to lead the Series B financing is a testament to our belief in the Company's vision and the potential of its innovative antibiotic programs," Dr. Burnell said. "We are confident that Revagenix, with its strong leadership and focused approach, is well-positioned to bring critical solutions to a global health challenge."…
PR Newswire
05/01/2024

Endotronix Submits PMA Application for its Cordella Pulmonary Artery Sensor…

"A cornerstone for managing NYHA class III heart failure patients, PA pressure-guided therapy combined with strong patient engagement and integration of daily vital signs is an exciting advancement that has the potential to improve outcomes," stated Harry Rowland, CEO and co-founder of Endotronix. "Submitting this PMA application is a significant regulatory milestone and brings us one step closer to the expected commercial launch of the Cordella Sensor in the second half of this…
PR Newswire
05/01/2024

Compass Pathways and Greenbrook TMS enter into three-year research collaboration…

Three-year research collaboration will investigate the development of scalable, commercial delivery models for COMP360 psilocybin treatment, if FDA-approved ®(esketamine nasal spray)—FDA-cleared, non-invasive therapies for the treatment of major depressive disorder and other mental health disorders, in the United States—today jointly announced that they have entered into a three-year research collaboration agreement to explore delivery models for investigational COMP360 psilocybin...
Nasdaq GlobeNewswire
05/01/2024

EndoQuest Robotics Partners with OMNIVISION to Equip Flexible Robotic System…

"We are excited to be able to incorporate OMNIVISION's market-leading sensor technology into the visualization component of our first of its kind platform," said Kurt Azarbarzin, CEO of EndoQuest Robotics. "We recognize that advanced imaging is essential to enhancing physician capabilities, especially inside the lumen of the gastrointestinal (GI) tract. OMNIVISION's newest technology is ideal for our Flexible Robotic System." "We are excited to be able to incorporate…
PR Newswire
05/01/2024

Tiziana Life Sciences Files New Patent Application for Combination Therapy of…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced filing of a new patent application relating to composition and methods for combining GLP-1ra and foralumab, a fully human anti-CD3 antibody, to achieve further reductions in systemic and vascular inflammation associated with Type 2 Diabetes (T2D) and also in a separate population of patients with non T2D obesity. Effectiveness of GLP-1ra non T2D obesity was...
Nasdaq GlobeNewswire
05/01/2024

Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating…

ORION CORPORATIONPRESS RELEASE 05 JANUARY 2023 at 13:45 EET Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer OMAHA1 and OMAHA2a are the first Phase 3 trials to be initiated for ODM-208/MK5684 Orion Corporation (“Orion”) and MSD (known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada) have initiated two pivotal Phase 3 clinical...
Nasdaq GlobeNewswire
05/01/2024

Bioretec Ltd - Managers' transactions

Bioretec Oy - Managers' Transactions Bioretec Oy - Managers' Transactions Person subject to the notification requirement Name: Stephen Industries Inc Oy Position: Closely associated person (X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer Name: Kustaa Poutiainen Position: Member of the Board Issuer: Bioretec Oy LEI: 7437008736AG7HY51K13 Notification type: INITIAL NOTIFICATION Reference number: 48652/4/6 Transaction date: 2024-01-03 Outside a trading venue...
PR Newswire
05/01/2024

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT 2023

Sales in Zinzino's sales markets increased by 24% in the fourth quarter of 2023 compared with the same period last year and amounted to SEK 511.2 (413.3) million. Total revenues in the Group increased by 23 % in the fourth quarter and amounted to SEK 529.8 (429.3) million. Sales in Zinzino's sales markets increased by 24% in the fourth quarter of 2023 compared with the same period last year and amounted toSEK 511.2(413.3) million. Total revenues in the Group increased by 23 % in the fourth...
PR Newswire
05/01/2024

VALNEVA - Declaration of shares and voting rights: December 31, 2023

VALNEVADeclaration of shares and voting rightsDecember 31, 2023__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: January 5, 2024 Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights* Description of the...
Nasdaq GlobeNewswire
05/01/2024

Sobi's Chairman of the Board resigns due to health reasons

"We regret that Bo Jesper needs to resign, and we thank him for his valuable contributions to Sobi", says Annette Clancy, Sobi's incoming Chair of the Board. "We regret thatBo Jesperneeds to resign, and we thank him for his valuable contributions to Sobi", saysAnnette Clancy, Sobi's incoming Chair of the Board. Sobi Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access…
PR Newswire
05/01/2024

Addex to Present at Biotech Showcase™ 2024

CEO to provide update on allosteric modulator pipeline clinical and preclinical development Geneva, Switzerland, January 5, 2024 - Addex Therapeutics(SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, will present atBiotech Showcasebeing held in San Francisco, January 8-10, 2024.In his presentation, scheduled for Monday January 8, 2024 at 4:30...
Nasdaq GlobeNewswire
05/01/2024

Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced…

Tablet-burden and dysphagia are well-documented challenges for prostate cancer patients, and the development of a 160mg, single tablet per day regimen enabled by Nanoform technology and formulation expertise may be preferable for patients in need of reducing their total number of daily pills. Tablet-burden and dysphagia are well-documented challenges for prostate cancer patients, and the development of a 160mg, single tablet per day regimen enabled by Nanoform technology and formulation...
PR Newswire
05/01/2024
Altri  Comunicati